B+
Bull case
25%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
OCGN
OcugenANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A favorable OCU400 pivotal readout and execution of the Roots regional agreement could improve the regulatory and financing outlook. OCU410 has entered Phase 3, but its pivotal outcome remains distant.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Ocugen reports recurring operating losses and negative operating cash flow; management's stated runway into 2028 depends on assumptions and does not eliminate financing risk. #SEC-10Q-2026-08-06 #SEC-8K-2026-08-06
Momentum
92
Value
41
Sentiment
84
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.80 · Bull $1.40 · Bear $0.30Analysis 2026-10-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $12.17
Why
Momentum92 · Δ7d -
Value41 · Δ7d -0.1
Sentiment84 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Ocugen reports recurring operating losses and negative operating cash flow; management's stated runway into 2028 depends on assumptions and does not eliminate financing risk. #SEC-10Q-2026-08-06 #SEC-8K-2026-08-06
- • Roots sales milestones and royalties depend on regulatory approval, commercialization, and sales in the licensed territory. #SEC-8K-2026-10-14
- • The adverse OCU410ST interim direction, binary OCU400 trial risk, continuing operating losses, and potential future dilution could outweigh partnership optionality.
Catalyst clock
2026-12-22
Postponed authorized-share vote
Lead driver: Sentiment · See AI snapshot
Momentum
92
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
84
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 91.8 / Value 40.6 / Sentiment 83.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-24. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.80
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.30
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$240.23M
Beta
3.49
Shares Out
339.11M
P/E (TTM) · Derived
-3.1
P/S (TTM)
84.33
P/FCF (TTM) · Derived
-3.72
Rev YoY
+8.4%
EPS YoY
+45.3%
Gross Margin
+37.0%
Op Margin
-1112.9%
Net Debt
$14.57M
Current Ratio
0.80
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data